UroGen Pharma CMO sells 10,000 shares under trading plan

UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported an open-market sale of 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share.

Rhea-AI Filing Summary

UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported an open-market sale of 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share. The transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan and represents the final sale under that plan. Following this sale, Schoenberg holds 119,763 Ordinary Shares directly.

Insights

Insider trading & governance analyst

Planned CMO share sale under 10b5-1, with substantial holdings retained.

Chief Medical Officer Mark Schoenberg executed an open-market sale of 10,000 UroGen Pharma Ordinary Shares at a weighted average of $40.00 per share. The filing shows this as a standard disposition of non-derivative equity.

The sale occurred under a pre-established Rule 10b5-1(c) trading plan adopted on August 15, 2025, and the footnote states this is the final sale under that plan. Such plans are designed to systematize trading and reduce the significance of timing decisions.

After the transaction, Schoenberg directly holds 119,763 Ordinary Shares, indicating an ongoing equity stake. There are no derivative positions reported in this filing, and no indication of unusual governance or control changes tied to this transaction.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Schoenberg Mark

Role Chief Medical Officer

Sold 10,000 shs ($400K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	10,000	$40.00	$400K

Holdings After Transaction: Ordinary Shares — 119,763 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025. This transaction represents the final sale under such trading plan.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 and $40.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Key Figures

Shares sold: 10,000 Ordinary Shares Weighted average sale price: $40.00 per share Post-transaction holdings: 119,763 Ordinary Shares +2 more

5 metrics

Shares sold 10,000 Ordinary Shares Open-market sale of non-derivative equity by Chief Medical Officer on 2026-07-09

Weighted average sale price $40.00 per share Weighted average price reported for the 10,000 shares sold

Post-transaction holdings 119,763 Ordinary Shares Shares directly held by Mark Schoenberg following the reported sale

Price range of sales $40.00 to $40.02 per share Range of individual sale prices across multiple transactions included in the Form 4

10b5-1 plan adoption date August 15, 2025 Adoption date of the Rule 10b5-1(c) trading plan governing this sale

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale

3 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

What did UroGen Pharma (URGN) Chief Medical Officer Mark Schoenberg report in this Form 4?

Mark Schoenberg reported an open-market sale of 10,000 UroGen Pharma Ordinary Shares at a weighted average price of $40.00 per share. The transaction was disclosed as a non-derivative sale and is detailed in a Form 4 insider trading report.

How many URGN shares did Mark Schoenberg sell and at what price?

Mark Schoenberg sold 10,000 Ordinary Shares of UroGen Pharma at a weighted average price of $40.00 per share. A footnote explains that individual sale prices ranged from $40.00 to $40.02 across multiple transactions.

How many UroGen Pharma (URGN) shares does Mark Schoenberg hold after this transaction?

After the reported sale, Mark Schoenberg directly holds 119,763 UroGen Pharma Ordinary Shares. This figure reflects his position immediately following the 10,000-share open-market disposition disclosed in the Form 4 filing.

Was the URGN insider sale by Mark Schoenberg made under a Rule 10b5-1 trading plan?

Yes, the sale was executed pursuant to a duly adopted Rule 10b5-1(c) trading plan. A footnote states the plan was adopted on August 15, 2025, and that this transaction represents the final sale under that plan.

What is the price range for the URGN shares sold by Mark Schoenberg in this Form 4?

The reported weighted average sale price was $40.00 per share, with individual trades between $40.00 and $40.02. The insider has undertaken to provide full trade-by-trade pricing information upon request to the issuer, its security holders, or SEC staff.

What role does Mark Schoenberg hold at UroGen Pharma (URGN) in this insider filing?

Mark Schoenberg is identified as the Chief Medical Officer of UroGen Pharma Ltd. The Form 4 indicates he is an officer of the company and reports this open-market sale of Ordinary Shares in that capacity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/10/2026 - 02:18 PM Accepted by SEC EDGAR 07/10/2026 - 02:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schoenberg Mark

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/09/2026		S(1)		10,000	D	$40(2)	119,763	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025. This transaction represents the final sale under such trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 and $40.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

	/s/ Jason D. Smith, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)